# Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis (RA) Patients

> **NCT01288287** · — · COMPLETED · sponsor: **UCB Pharma** · enrollment: 149 (actual)

## Conditions studied

- Arthritis,Rheumatoid

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01288287
- **Lead sponsor:** UCB Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2014-10
- **Final completion:** 2014-12
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2016-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01288287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01288287, "Long Term Effects of an Early Response to Certolizumab Pegol (CZP, Cimzia®) in Rheumatoid Arthritis (RA) Patients". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01288287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*